Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens

  • Edmund J. Gosselin
  • Constantine Bitsaktsis
  • Ying Li
  • Bibiana V. Iglesias
Review

Abstract

Numerous studies have demonstrated that targeting immunogens to Fcγ receptors (FcγR) on antigen (Ag)-presenting cells (APC) can enhance humoral and cellular immunity in vitro and in vivo. FcγR are classified based on their molecular weight, IgG-Fc binding affinities, IgG subclass binding specificity, and cellular distribution and they consist of activating and inhibitory receptors. However, despite the potential advantages of targeting Ag to FcR at mucosal sites, very little is known regarding the role of FcR in mucosal immunity or the efficacy of FcR-targeted mucosal vaccines. In addition, recent work has suggested that FcRn is present in the lungs of adult mice and humans and can transport FcRn-targeted Ag to FcγR-bearing APC within mucosal lymphoid tissue. In this review we will discuss the need for new vaccine strategies, the potential for FcR-targeted vaccines to fill this need, the impact of activating versus inhibitory FcγR on FcR-targeted vaccination, the significance of focusing on mucosal immunity, as well as caveats that could impact the use of FcR targeting as a mucosal vaccine strategy.

Keywords

vaccine mucosal immunity Fc receptors 

Abbreviations

Ab

antibody/antibodies

Ag

antigen(s)

APC

Ag-presenting cell(s)

DC

dendritic cell(s)

macrophage(s)

Th

T helper cell(s)

CTB

cholera toxin B

FcR

Fc receptor(s)

mAb

monoclonal Ab

ITAM

immunoreceptor tyrosine-based activation motif

ITIM

immunoreceptor tyrosine-based inhibition motif

TT

tetanus toxoid

KO

knockout

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. (2007): Cold shower for AIDS vaccines. Nat Med 13:1389–1390Google Scholar
  2. Adamova E, Walsh MC, Gosselin DR et al (2005) Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human Fcgamma receptor type I using an anti-human Fcgamma receptor type I-streptavidin fusion protein in an adjuvant-free system. Immunol Invest 34: 417–429PubMedCrossRefGoogle Scholar
  3. Amigorena S, Bonnerot C (1999) Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin Immunol 11: 385–390PubMedCrossRefGoogle Scholar
  4. Anjuere F, George-Chandy A, Audant F et al (2003) Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J Immunol 170: 1586–1592PubMedGoogle Scholar
  5. Anthony LS, Ghadirian E, Nestel FP et al (1989) The requirement for gamma interferon in resistance of mice to experimental tularemia. Microb Pathog 7: 421–428PubMedCrossRefGoogle Scholar
  6. Appay V, Douek DC, Price DA (2008) CD8+ T cell efficacy in vaccination and disease. Nat Med 14: 623–628PubMedCrossRefGoogle Scholar
  7. Areas AP, Oliveira ML, Miyaji EN et al (2004) Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun 321: 192–196PubMedCrossRefGoogle Scholar
  8. Armstrong A, Eck SL (2003) EpCAM: A new therapeutic target for an old cancer antigen. Cancer Biol Ther 2: 320–326PubMedGoogle Scholar
  9. Arulanandam BP, O’Toole M, Metzger DW (1999) Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis 180: 940–949PubMedCrossRefGoogle Scholar
  10. Bayry J, Lacroix-Desmazes S, Kazatchkine MD et al (2005) Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol 175: 15–20PubMedGoogle Scholar
  11. Bitonti AJ, Dumont JA, Low SC et al (2004) Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 101: 9763–9768PubMedCrossRefGoogle Scholar
  12. Boruchov AM, Heller G, Veri MC (2005) Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 115: 2914–2923PubMedCrossRefGoogle Scholar
  13. Boyaka PN, Lillard JW Jr, McGhee J (1999) Interleukin 12 and innate molecules for enhanced mucosal immunity. Immunol Res 20: 207–217PubMedCrossRefGoogle Scholar
  14. Brady LJ, van Tilburg ML, Alford CE et al (2000) Monoclonal antibody-mediated modulation of the humoral immune re sponse against mucosally applied Streptococcus mutans. Infect Immun 68: 1796–1805PubMedCrossRefGoogle Scholar
  15. Braun MC, He J, Wu CY et al (1999) Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. J Exp Med 189: 541–552PubMedCrossRefGoogle Scholar
  16. Brooks DG, Qiu WQ, Luster AD et al (1989) Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J Exp Med 170: 1369–1385Google Scholar
  17. Casadevall A (1998) Antibody-mediated protection against intracellular pathogens. Trends Microbiol 6: 102–107PubMedCrossRefGoogle Scholar
  18. Cassel DL, Keller MA, Surrey S et al (1993) Differential expression of Fc gamma RIIA, Fc gamma RIIB and Fc gamma RIIC in hematopoietic cells: analysis of transcripts. Mol Immunol 30: 451–460PubMedCrossRefGoogle Scholar
  19. Celis E, Zurawski VR Jr, Chang TW (1984) Regulation of T-cell function by antibodies: enhancement of the response of human T-cell clones to hepatitis B surface antigen by antigenspecific monoclonal antibodies. Proc Natl Acad Sci USA 81: 6846–6850PubMedCrossRefGoogle Scholar
  20. Chargelegue D, Drake PM, Obregon P et al (2005) Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants. Infect Immun 73: 5915–5922PubMedCrossRefGoogle Scholar
  21. Coombes BK, Valdez Y, Finlay BB (2004) Evasive maneuvers by secreted bacterial proteins to avoid innate immune responses. Curr Biol 14: R856–867PubMedCrossRefGoogle Scholar
  22. Cooper AM, Adams LB, Dalton DK et al (2002) IFN-gamma and NO in mycobacterial disease: new jobs for old hands. Trends Microbiol 10: 221–226PubMedCrossRefGoogle Scholar
  23. Daeron M (1997) Fc receptor biology. Annu Rev Immunol 15: 203–234PubMedCrossRefGoogle Scholar
  24. Dijstelbloem HM, van de Winkel JG, Kallenberg CG (2001) Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol 22: 510–516PubMedCrossRefGoogle Scholar
  25. Edelson BT, Unanue ER (2001) Intracellular antibody neutralizes Listeria growth. Immunity 14: 503–512PubMedCrossRefGoogle Scholar
  26. Fanger NA, Voigtlaender D, Liu C (1997) Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells. J Immunol 158: 3090–3098PubMedGoogle Scholar
  27. Feng HM, Whitworth T, Olano JP et al (2004) Fc-dependent polyclonal antibodies and antibodies to outer membrane proteins A and B, but not to lipopolysaccharide, protect SCID mice against fatal Rickettsia conorii infection. Infect Immun 72: 2222–2228PubMedCrossRefGoogle Scholar
  28. Finlay BB, McFadden G (2006) Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124: 767–782PubMedCrossRefGoogle Scholar
  29. Fridman WH (1993) Regulation of B-cell activation and antigen presentation by Fc receptors. Curr Opin Immunol 5: 355–360PubMedCrossRefGoogle Scholar
  30. Gessner JE, Heiken H, Tamm A et al (1998) The IgG Fc receptor family. Ann Hematol 76: 231–248PubMedCrossRefGoogle Scholar
  31. Getahun A, Dahlstrom J, Wernersson S et al (2004) IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc gamma receptors. J Immunol 172: 5269–5276PubMedGoogle Scholar
  32. Gonzales NR, De Pascalis R, Schlom J et al (2005) Minimizing the mmunogenicity of antibodies for clinical application. Tumour Biol 26: 31–43PubMedCrossRefGoogle Scholar
  33. Gosselin EJ, Wardwell K, Gosselin DR et al (1992) Enhanced antigen presentation using human Fc gamma receptor (monocyte/ macrophage)-specific immunogens. J Immunol 149: 3477–3481PubMedGoogle Scholar
  34. Graziano RF, Tempest PR, White P et al (1995) Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody. J Immunol 155: 4996–5002PubMedGoogle Scholar
  35. Guyre CA, Keler T, Swink SL et al (2001) Receptor modulation by Fc gamma RI-specific fusion proteins is dependent on receptor number and modified by IgG. J Immunol 167: 6303–6311PubMedGoogle Scholar
  36. Guyre PM, Graziano RF, Goldstein J et al (1997) Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother 45: 146–148PubMedCrossRefGoogle Scholar
  37. Guyre PM, Graziano RF, Vance BA et al (1989) Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J Immunol 143: 1650–1655PubMedGoogle Scholar
  38. Heijnen IA, van Vugt MJ, Fanger NA et al (1996) Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 97: 331–338PubMedCrossRefGoogle Scholar
  39. Heyman B (2000) Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu Rev Immunol 18: 709–737PubMedCrossRefGoogle Scholar
  40. Hibbs ML, Walker ID, Kirszbaum L et al (1986) The murine Fc receptor for immunoglobulin: purification, partial amino acid sequence, and isolation of cDNA clones. Proc Natl Acad Sci USA 83: 6980–6984PubMedCrossRefGoogle Scholar
  41. Holmgren J, Harandi AM, Czerkinsky C (2003) Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev Vaccines 2: 205–217PubMedCrossRefGoogle Scholar
  42. Isaka M, Komiya T, Takahashi M et al (2004) Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine. Vaccine 22: 3061–3068PubMedCrossRefGoogle Scholar
  43. Isaka M, Yasuda Y, Kozuka S et al (1999) Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine 18: 743–751PubMedCrossRefGoogle Scholar
  44. Isaka M, Yasuda Y, Taniguchi T et al (2003) Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine 21: 1165–1173PubMedCrossRefGoogle Scholar
  45. Ivan E, Colovai AI (2006) Human Fc receptors: critical targets in the treatment of autoimmune diseases and transplant rejections. Hum Immunol 67: 479–491PubMedCrossRefGoogle Scholar
  46. Jackson RJ, Fujihashi K, Xu-Amano J et al (1993) Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun 61: 4272–4279PubMedGoogle Scholar
  47. Jelley-Gibbs DM, Plitnick LM, Gosselin EJ (1999) Differences in IgG subclass do not effect immune complex-enhanced T cell activation despite differential binding to antigen presenting cells. Hum Immunol 60: 469–478PubMedCrossRefGoogle Scholar
  48. Jennings H (1992) Further approaches for optimizing polysaccharide- protein conjugate vaccines for prevention of invasive bacterial disease. J Infect Dis 165(suppl 1): S156–159PubMedGoogle Scholar
  49. Keler T, Guyre PM, Vitale LA et al (2000) Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J Immunol 165: 6738–6742PubMedGoogle Scholar
  50. Kensil CR, Mo AX, Truneh A (2004) Current vaccine adjuvants: an overview of a diverse class. Front Biosci 9: 2972–2988PubMedCrossRefGoogle Scholar
  51. Keren DF (1987) Models to follow secretory IgA response to mucosal infections. Pathol Immunopathol Res 6: 128–136PubMedCrossRefGoogle Scholar
  52. Kirimanjeswara GS, Golden JM, Bakshi CS et al (2007) Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol, 179: 532–539Google Scholar
  53. Klinman DM, Conover J, Coban C (1999) Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun 67: 5658–5663PubMedGoogle Scholar
  54. Kovacsovics-Bankowski M, Clark K, Benacerraf B et al (1993) Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 90: 4942–4946PubMedCrossRefGoogle Scholar
  55. Law M, Hangartner L (2008) Antibodies against viruses: passive and active immunization. Curr Opin Immunol 20: 486–492PubMedCrossRefGoogle Scholar
  56. Leiby DA, Fortier AH, Crawford RM et al (1992) In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect Immun 60: 84–89PubMedGoogle Scholar
  57. Lesinski GB, Westerink MA (2001) Novel vaccine strategies to T-independent antigens. J Microbiol Methods 47: 135–149PubMedCrossRefGoogle Scholar
  58. Li JS, Yager E, Reilly M (2001) Outer membrane protein-specific monoclonal antibodies protect SCID mice from fatal infection by the obligate intracellular bacterial pathogen Ehrlichia chaffeensis. J Immunol 166: 1855–1862PubMedGoogle Scholar
  59. Liu C, Goldstein J, Graziano RF et al (1996) F(c)gammaRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes. J Clin Invest 98: 2001–2007PubMedCrossRefGoogle Scholar
  60. London CA, Abbas AK, Kelso A (1998) Helper T cell subsets: heterogeneity, functions and development. Vet Immunol Immunopathol 63: 37–44PubMedCrossRefGoogle Scholar
  61. Luci C, Hervouet C, Rousseau D et al (2006) Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin. J Immunol 176: 2749–2757PubMedGoogle Scholar
  62. Lynch JM, Briles DE, Metzger DW (2003) Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 71: 4780–4788PubMedCrossRefGoogle Scholar
  63. Marinaro M, Staats HF, Hiroi T et al (1995) Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 155: 4621–4629PubMedGoogle Scholar
  64. Marriott JB (1997) TNF-alpha antagonists: monoclonal antibodies, soluble receptors, thalidomide and other novel approaches. Expert Opin Investig Drugs 6: 1105–1108PubMedCrossRefGoogle Scholar
  65. McCluskie MJ, Weeratna RD (2001) Novel adjuvant systems. Curr Drug Targets Infect Disord 1: 263–271PubMedCrossRefGoogle Scholar
  66. McCluskie MJ, Wen YM, Di Q et al (1998) Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol 11: 245–252PubMedCrossRefGoogle Scholar
  67. McGhee JR, Kiyono H (1994) Effective mucosal immunity. Current concepts for vaccine delivery and immune response analysis. Int J Technol Assess Health Care 10: 93–106Google Scholar
  68. McSorley SJ, Jenkins MK (2000) Antibody is required for protection against virulent but not attenuated Salmonella enterica serovar typhimurium. Infect Immun 68: 3344–3348PubMedCrossRefGoogle Scholar
  69. Miettinen HM, Matter K, Hunziker W et al (1992) Fc receptor endocytosis is controlled by a cytoplasmic domain determinant that actively prevents coated pit localization. J Cell Biol 116: 875–888PubMedCrossRefGoogle Scholar
  70. Miettinen HM, Rose JK, Mellman I (1989) Fc receptor isoforms exhibit distinct abilities for coated pit localization as a result of cytoplasmic domain heterogeneity. Cell 58: 317–327PubMedCrossRefGoogle Scholar
  71. Moore AC, Hutchings CL (2007) Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity. Expert Rev Vaccines 6: 111–121PubMedCrossRefGoogle Scholar
  72. Moore T, Ekworomadu CO, Eko FO et al (2003) Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis 188: 617–624PubMedCrossRefGoogle Scholar
  73. Neefjes JJ, Momburg F (1993) Cell biology of antigen presentation. Curr Opin Immunol 5: 27–34PubMedCrossRefGoogle Scholar
  74. Nimmerjahn F, Bruhns P, Horiuchi K et al (2005) FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23: 41–51PubMedCrossRefGoogle Scholar
  75. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310: 1510–1512PubMedCrossRefGoogle Scholar
  76. Nimmerjahn F, Ravetch JV (2007) Fc-receptors as regulators of immunity. Adv Immunol 96: 179–204PubMedCrossRefGoogle Scholar
  77. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34–47PubMedCrossRefGoogle Scholar
  78. O’Hagan DT, MacKichan ML, Singh M (2001) Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 18: 69–85PubMedCrossRefGoogle Scholar
  79. Ober RJ, Radu CG, Ghetie V et al (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13: 1551–1559PubMedCrossRefGoogle Scholar
  80. Ono M, Bolland S, Tempst P et al (1996) Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 383: 263–266PubMedCrossRefGoogle Scholar
  81. Petrovsky N (2006) Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 24(suppl 2): S2–2629PubMedGoogle Scholar
  82. Presta LG, Shields RL, Namenuk AK et al (2002) Engineering therapeutic antibodies for improved function. Biochem Soc Trans 30: 487–490PubMedCrossRefGoogle Scholar
  83. Qiao SW, Kobayashi K, Johansen FE et al (2008) Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA 105: 9337–9342PubMedCrossRefGoogle Scholar
  84. Rafiq K, Bergtold A, Clynes R (2002) Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110: 71–79PubMedGoogle Scholar
  85. Ravetch JV, Kinet JP (1991) Fc receptors. Annu Rev Immunol 9: 457–492PubMedGoogle Scholar
  86. Ravetch JV, Luster AD, Weinshank R et al (1986) Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors. Science 234: 718–725PubMedCrossRefGoogle Scholar
  87. Rawool DB, Bitsaktsis C, Li Y et al (2008) Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 180: 5548–5557PubMedGoogle Scholar
  88. Regnault A, Lankar D, Lacabanne V et al (1999) Fcgamma receptor- mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189: 371–380PubMedCrossRefGoogle Scholar
  89. Rhodin NR, Van Tilburg ML, Oli MW et al (2004) Further characterization of immunomodulation by a monoclonal antibody against Streptococcus mutans antigen P1. Infect Immun 72: 13–21PubMedCrossRefGoogle Scholar
  90. Robinson HL (2007) HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 82: 686–693PubMedCrossRefGoogle Scholar
  91. Rocha CD, Caetano BC, Machado AV et al (2004) Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol 7: 83–94PubMedGoogle Scholar
  92. Rock KL (1996) A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17: 131–137PubMedCrossRefGoogle Scholar
  93. Romagnani S (2000) T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 85: 9–18 quiz 18, 21PubMedCrossRefGoogle Scholar
  94. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715–725PubMedCrossRefGoogle Scholar
  95. Russell MW, Mestecky J (1988) Induction of the mucosal immune response. Rev Infect Dis 10(suppl 2): S440–446PubMedGoogle Scholar
  96. Salmon JE, Pricop L (2001) Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. Arthritis Rheum 44: 739–750PubMedCrossRefGoogle Scholar
  97. Sant AJ, Chaves FA, Krafcik FR et al (2007) Immunodominance in CD4 T-cell responses: implications for immune responses to influenza virus and for vaccine design. Expert Rev Vaccines 6: 357–368PubMedCrossRefGoogle Scholar
  98. Singh M, O’Hagan DT (2002) Recent advances in vaccine adjuvants. Pharm Res 19: 715–728PubMedCrossRefGoogle Scholar
  99. Sjostedt A, North RJ, Conlan JW (1996) The requirement of tumour necrosis factor-alpha and interferon-gamma for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum. Microbiology 142(Pt 6): 1369–1374PubMedCrossRefGoogle Scholar
  100. Snider DP, Kaubisch A, Segal DM (1990) Enhanced antigen immunogenicity induced by bispecific antibodies. J Exp Med 171: 1957–1963PubMedCrossRefGoogle Scholar
  101. Spiekermann GM, Finn PW, Ward ES (2002) Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med 196: 303–310PubMedCrossRefGoogle Scholar
  102. Sun K, Salmon SL, Lotz SA et al (2007) Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect Immun 75: 1196–1202PubMedCrossRefGoogle Scholar
  103. Svanborg C, Godaly G, Hedlund M (1999) Cytokine responses during mucosal infections: role in disease pathogenesis and host defence. Curr Opin Microbiol 2: 99–105PubMedCrossRefGoogle Scholar
  104. Takashima Y, Tsukamoto M, Ota H et al (2005) Immunization with pseudorabies virus harboring Fc domain of IgG makes a contribution to protection of mice from lethal challenge. Vaccine 23: 3775–3782PubMedCrossRefGoogle Scholar
  105. Tew JG, Wu J, Qin D (1997) Follicular dendritic cells and presentation of antigen and costimulatory signals to B cells. Immunol Rev 156: 39–52PubMedCrossRefGoogle Scholar
  106. Toida N, Hajishengallis G, Wu HY et al (1997) Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T-helper-cell responses in gut-associated lymphoid tissues. Infect Immun 65: 909–915PubMedGoogle Scholar
  107. Tridandapani S, Kelley T, Pradhan M et al (1997) Recruitment and phosphorylation of SH2-containing inositol phosphatase and Shc to the B-cell Fc gamma immunoreceptor tyrosine-based inhibition motif peptide motif. Mol Cell Biol 17: 4305–4311PubMedGoogle Scholar
  108. van de Winkel JG, Anderson CL (1991) Biology of human immunoglobulin G Fc receptors. J Leukoc Biol 49: 511–524PubMedGoogle Scholar
  109. Vaughan TJ, Osbourn JK, Tempest PR (1998) Human antibodies by design. Nat Biotechnol 16: 535–539PubMedCrossRefGoogle Scholar
  110. Vogel FR (2000) Improving vaccine performance with adjuvants. Clin Infect Dis 30(suppl 3): S266–270PubMedCrossRefGoogle Scholar
  111. Wallace PK, Tsang KY, Goldstein J et al (2001) Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J Immunol Methods 248: 183–194PubMedCrossRefGoogle Scholar
  112. Walsh MC, Banas JA, Mudzinski SP et al (2003) A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcgammaRI-streptavidin construct and microspheres coated with biotinylated-antigen. Biomol Eng 20: 21–33PubMedCrossRefGoogle Scholar
  113. Weltzin R, Monath TP (1999) Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev 12: 383–393PubMedGoogle Scholar
  114. Wernersson S, Karlsson MC, Dahlstrom J et al (1999) IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice. J Immunol 163: 618–622PubMedGoogle Scholar
  115. Wernersson S, Kleinau S, Heyman B (2000) Immune complexmediated enhancement of antibody responses without induction of delayed-type hypersensitivity. Scand J Immunol 52: 563–569PubMedCrossRefGoogle Scholar
  116. Wu HY, Russell MW (1998) Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine 16: 286–292PubMedCrossRefGoogle Scholar
  117. Yager E, Bitsaktsis C, Nandi B et al (2005) Essential role for humoral immunity during Ehrlichia infection in immunocompetent mice. Infect Immun 73: 8009–8016PubMedCrossRefGoogle Scholar
  118. Yee D, Rhinehart-Jones TR, Elkins KL (1996) Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J Immunol 157: 5042–5048PubMedGoogle Scholar
  119. Yewdell JW, Bennink JR (1990) The binary logic of antigen processing and presentation to T cells. Cell 62: 203–206PubMedCrossRefGoogle Scholar
  120. Yoshida M, Claypool SM, Wagner JS et al (2004) Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20: 769–783PubMedCrossRefGoogle Scholar
  121. Zimmerman RK, Middleton DB, Burns IT et al (2003) Routine vaccines across the life span, 2003. J Fam Pract 52: S1–21PubMedGoogle Scholar

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2009

Authors and Affiliations

  • Edmund J. Gosselin
    • 1
  • Constantine Bitsaktsis
    • 1
  • Ying Li
    • 1
  • Bibiana V. Iglesias
    • 1
  1. 1.Center for Immunology and Microbial Disease, MC-151Albany Medical CollegeAlbanyUSA

Personalised recommendations